知镜 Cognispect · 医学文献与研究工作台

CE9A215 (inotodiol) ameliorates oxazolone-induced atopic dermatitis by targeting mast cells and proinflammatory cytokines.

Nguyen TMN, Do TT, Ban S, Hwang SB, Nguyen VD, Park JT, Kim H.
The Journal of pharmacology and experimental therapeutics · 2026-07-31 · PMID 42710452

文献摘要

Atopic dermatitis (AD) is a chronic inflammatory skin disorder requiring long-term management; however, current therapeutics are often limited by side effects. CE9A215 (inotodiol), recently identified as a selective liver X receptor β agonist, has shown potential for regulating inflammation with a favorable safety profile. This study investigated the therapeutic efficacy and underlying mechanisms of CE9A215 in a murine model of oxazolone-induced chronic AD. We evaluated cellular responses using human mast cells (LUVA) and macrophages (RAW264.7) and assessed in vivo efficacy after oral administration of CE9A215 (4 and 10 mg/kg) for 9 days. In vitro, CE9A215 inhibited mast cell degranulation more effectively than dexamethasone and significantly suppressed lipopolysaccharide-induced proinflammatory cytokine production in macrophages. In vivo, CE9A215 treatment markedly ameliorated AD-like clinical symptoms, reducing epidermal hyperplasia to levels comparable to dexamethasone. Mechanistically, CE9A215 stabilized mast cells and macrophages within the dorsal skin, leading to significantly reduced levels of β-chymase in both serum and tissue. Furthermore, it downregulated the expression of key proinflammatory cytokines (tumor necrosis factor α and interleukin-1β) and T helper 2-associated cytokines (interleukin-4) in skin lesions. Notably, although systemic total IgE levels remained unchanged, the specific suppression of cutaneous interleukin-4 and inflammatory mediators indicates targeted regulation of the local inflammatory cascade. These findings suggest that CE9A215 alleviates AD pathology through liver X receptor β-mediated stabilization of mast cells and immune modulation, positioning it as a promising therapeutic candidate for chronic AD. SIGNIFICANCE STATEMENT: Current therapies for atopic dermatitis, including corticosteroids, are often limited by long-term side effects. This study identifies CE9A215 (inotodiol) as a potent therapeutic agent that ameliorates chronic atopic dermatitis pathology by targeting liver X receptor β. Unlike nonselective liver X receptor agonists known to induce hepatic steatosis, CE9A215 selectively stabilizes mast cells and macrophages without systemic toxicity.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。